𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression

✍ Scribed by Houston, A; Bennett, M W; O'Sullivan, G C; Shanahan, F; O'Connell, J

Book ID
109997743
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
304 KB
Volume
89
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fas ligand expression in primary colon a
Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
✍ O'Connell, Joe; Bennett, Michael W.; O'Sullivan, Gerald C.; Roche, Desmond; Kell 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 2 views

Fas ligand (FasL) kills sensitive Fas receptor (FasR)-bearing cells by inducing apoptosis. FasL expressed by non-lymphoid cells within the eye and the testis mediates immune privilege by inducing apoptosis of Fas-sensitive infiltrating pro-inflammatory immune effector cells. It has previously been d

The role of Fas ligand and transforming
The role of Fas ligand and transforming growth factor β in tumor progression : Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy
✍ Ryungsa Kim; Manabu Emi; Kazuaki Tanabe; Yoko Uchida; Tetsuya Toge 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

## Abstract Despite the fact that expression of Fas ligand (FasL) in cytotoxic T lymphocytes (CTLs) and in natural killer (NK) cells plays an important role in Fas‐mediated tumor killing, During tumor progression FasL‐expressing tumor cells are involved in __counterattacking__ to kill tumor‐infiltr